.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Chubb
Federal Trade Commission
Cerilliant
Farmers Insurance
Citi
Queensland Health
US Army
Deloitte
Chinese Patent Office

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,932,610

« Back to Dashboard

Which drugs does patent 8,932,610 protect, and when does it expire?


Patent 8,932,610 protects OTOVEL and is included in one NDA.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 8,932,610

Title:Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
Abstract: A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.
Inventor(s): Ruiz I Pol; Jaume (Esplugues de Llobregat, ES), Izquierdo Torres; Francisca (Esplugues de Llobregat, ES)
Assignee: Laboratorios Salvat, S.A. (Esplugues de Llobregat (Barcelona), ES)
Application Number:12/730,681
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Laboratorios Salvat
OTOVEL
ciprofloxacin hydrochloride; fluocinolone acetonide
SOLUTION/DROPS;OTIC208251-001Apr 29, 2016RXYesYes► Subscribe► SubscribeY TREATMENT OF ACUTE OTITIS MEDIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,932,610

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10155005Mar 1, 2010

International Patent Family for Patent: 8,932,610

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina080368► Subscribe
Australia2011223095► Subscribe
Canada2790652► Subscribe
China102811741► Subscribe
Denmark2366408► Subscribe
European Patent Office2366408► Subscribe
Spain2391721► Subscribe
Hong Kong1162145► Subscribe
Japan2013521245► Subscribe
Japan5744922► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Department of Justice
AstraZeneca
Express Scripts
Federal Trade Commission
McKesson
Boehringer Ingelheim
Dow
Citi
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot